Huperzine A alleviates neuroinflammation, oxidative stress and improves cognitive function after repetitive traumatic brain injury
- 385 Downloads
Traumatic brain injury (TBI) may trigger secondary injury cascades including endoplasmic reticulum stress, oxidative stress, and neuroinflammation. Unfortunately, there are no effective treatments targeting either primary or secondary injuries that result in long-term detrimental consequences. Huperzine A (HupA) is a potent acetylcholinesterase inhibitor (AChEI) that has been used treatment of Alzheimer’s disease (AD). This study aimed to explore the neuroprotective effects of HupA in TBI and its possible mechanisms. Repetitive mild closed head injury (CHI) model was used to mimic concussive TBI. Mice were randomly assigned into three groups including sham, vehicle-treated and HupA-treated injured mice. The HupA was given at dose of 1.0 mg/kg/day and was initiated 30 min after the first injury, then administered daily for a total of 30 days. The neuronal functions including motor functions, emotion-like behaviors, learning and memory were tested. Axonal injury, reactive oxygen species (ROS), and neuroinflammation were examined as well. The results showed that injured mice treated with HupA had significant improvement in Morris water maze performance compared with vehicle-treated injured mice. HupA treatment significantly attenuated markers of neuroinflammation and oxidative stress in the injured mice. Taken together, HupA was effective in reducing neuroinflammation, oxidative stress and behavioral recovery after TBI. HupA is a promising candidate for treatment of TBI.
KeywordsTraumatic brain injury Huperzine A Nueroprotection Neuroinflammation Oxidative stress
The authors would like to thank Dr. Jianhua Qiu for his assistance with the revision English language.
Compliance with ethical standards
This work is supported by a grant from Guangzhou Education Bureau (1201421151).
Conflict of interest
No competing financial interests exist.
- Hayes JP et al (2017) Mild traumatic brain injury is associated with reduced cortical thickness in those at risk for Alzheimer’s disease. Brain. doi: 10.1093/brain/aww344
- Johnson MW, Stoll L, Rubio A, Troncoso J, Pletnikova O, Fowler DR, Li L (2011) Axonal injury in young pediatric head trauma: a comparison study of β-amyloid precursor protein (β-APP) Immunohistochemical staining in traumatic and nontraumatic deaths*. J Forensic Sci 56:1198–1205CrossRefPubMedPubMedCentralGoogle Scholar
- Kochanek PM et al (2016) Approach to modeling, therapy evaluation, drug selection, and biomarker assessments for a multicenter pre-clinical drug screening consortium for acute therapies in severe traumatic brain injury: operation brain trauma therapy. J Neurotrauma 33:513–522CrossRefPubMedGoogle Scholar
- Mei Z, Qiu J, Alcon S, Hashim J, Rotenberg A, Sun Y, Meehan WP 3rd, Mannix R (2017) Memantine improves outcomes after repetitive traumatic brain injury. Behav Brain Res. doi: 10.1016/j.bbr.2017.04.017
- Yang L et al (2017) DRα1-MOG-35-55 treatment reduces lesion volumes and improves neurological deficits after traumatic brain injury. Metab Brain Dis. doi: 10.1007/s11011-017-9991-6